📊 LFCR Key Takeaways
Is LFCR a Good Investment? Thesis Analysis
LIFECORE is a technically insolvent pharmaceutical company with negative stockholders' equity of -$10.5M, indicating liabilities exceed assets. Despite positive operating cash flow, the company is burning through equity with -$10.0M net losses and -$3.1M operating losses, while carrying a heavy $136M debt burden that it cannot service from operations (negative interest coverage of -0.5x).
Why Buy LFCR? Key Strengths
- Positive operating cash flow of $1.8M demonstrates core operations generate cash
- Strong liquidity ratios (current 2.80x, quick 1.67x) provide short-term solvency buffer
- Gross margin of 25% shows underlying business model has structural viability
LFCR Investment Risks to Consider
- Negative stockholders' equity of -$10.5M indicates technical insolvency and distress
- Operating income of -$3.1M and net losses of -$10.0M with -32.1% net margin show unprofitability
- Massive debt burden of $136M with negative interest coverage ratio (-0.5x) creates refinancing risk
- Free cash flow of only $25K with 0.1% FCF margin leaves no financial flexibility for growth or debt service
- Cash runway of ~10 years at current burn rate is inadequate given $136M debt maturity risks
Key Metrics to Watch
- Path to operating profitability and timeline to positive net income
- Stockholders' equity recovery - current negative equity is unsustainable
- Debt refinancing schedule and ability to service $136M long-term debt
- Operating cash flow sustainability and free cash flow improvement
- Revenue growth and gross margin maintenance in pharmaceutical segment
LFCR Financial Metrics
💡 AI Analyst Insight
The relatively thin 0.1% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.80x current ratio provides a solid financial cushion.
LFCR Profitability Ratios
LFCR vs Healthcare Sector
How LIFECORE BIOMEDICAL, INC. DE compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LFCR Overvalued or Undervalued?
Based on fundamental analysis, LIFECORE BIOMEDICAL, INC. DE has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LFCR Balance Sheet & Liquidity
LFCR 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LIFECORE BIOMEDICAL, INC. DE's revenue has declined by 78% over the 5-year period, indicating business contraction. The most recent EPS of $0.33 reflects profitable operations.
LFCR Growth Metrics (YoY)
LFCR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $24.7M | -$10.0M | $-0.29 |
| Q3 2025 | $35.2M | -$14.8M | $0.42 |
| Q2 2025 | $30.2M | $3.5M | $0.10 |
| Q1 2025 | $24.5M | -$10.8M | $-0.35 |
| Q3 2024 | $26.5M | -$10.8M | $0.42 |
| Q2 2024 | $21.9M | $3.5M | $0.10 |
| Q1 2024 | $23.7M | -$10.8M | $-0.35 |
| Q3 2023 | $27.6M | -$9.5M | $-0.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LFCR Capital Allocation
LFCR SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LIFECORE BIOMEDICAL, INC. DE (CIK: 0001005286)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LFCR
What is the AI rating for LFCR?
LIFECORE BIOMEDICAL, INC. DE (LFCR) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LFCR's key strengths?
Claude: Positive operating cash flow of $1.8M demonstrates core operations generate cash. Strong liquidity ratios (current 2.80x, quick 1.67x) provide short-term solvency buffer.
What are the risks of investing in LFCR?
Claude: Negative stockholders' equity of -$10.5M indicates technical insolvency and distress. Operating income of -$3.1M and net losses of -$10.0M with -32.1% net margin show unprofitability.
What is LFCR's revenue and growth?
LIFECORE BIOMEDICAL, INC. DE reported revenue of $31.1M.
Does LFCR pay dividends?
LIFECORE BIOMEDICAL, INC. DE does not currently pay dividends.
Where can I find LFCR SEC filings?
Official SEC filings for LIFECORE BIOMEDICAL, INC. DE (CIK: 0001005286) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LFCR's EPS?
LIFECORE BIOMEDICAL, INC. DE has a diluted EPS of $-0.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LFCR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LIFECORE BIOMEDICAL, INC. DE has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LFCR stock overvalued or undervalued?
Valuation metrics for LFCR: ROE of N/A (sector avg: 15%), net margin of -32.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LFCR stock in 2026?
Our dual AI analysis gives LIFECORE BIOMEDICAL, INC. DE a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LFCR's free cash flow?
LIFECORE BIOMEDICAL, INC. DE's operating cash flow is $1.8M, with capital expenditures of $1.7M. FCF margin is 0.1%.
How does LFCR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -32.1% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.80 (avg: 2).